Royal Bank of Canada Purchases 199,863 Shares of Stryker Corporation $SYK

Royal Bank of Canada grew its position in Stryker Corporation (NYSE:SYK) by 6.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,273,232 shares of the medical technology company’s stock after purchasing an additional 199,863 shares during the period. Royal Bank of Canada’s holdings in Stryker were worth $1,075,552,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Sankala Group LLC purchased a new stake in Stryker in the fourth quarter worth $26,000. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker in the 4th quarter worth about $27,000. Finally, DJE Kapital AG bought a new stake in Stryker in the 4th quarter valued at about $28,000. 77.09% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Up 2.9%

Shares of NYSE SYK opened at $346.59 on Wednesday. The business has a 50-day moving average of $315.76 and a 200-day moving average of $335.22. The firm has a market capitalization of $132.87 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 2.16 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $403.92.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the prior year, the firm posted $2.84 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is presently 40.74%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on SYK shares. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a report on Friday, May 1st. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a research report on Friday, May 1st. Finally, Barclays decreased their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $393.39.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.